The Effectiveness and Safety of FK-506 for the Treatment of Posner-Schlossman Syndrome
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness and safety of tacrolimus eye drops (FK-506) in the treatment of
Posner-Schlossman Syndrome. It is expected to collect 30 patients with PSS who are in the
Ophthalmology Department of Peking University Third Hospital. The included PSS patients were
divided into experimental group and control group using simple randomization method. Among
them, the experimental group was treated with FK-506 twice a day, and the control group was
treated with prednisolone acetate ophthalmic suspension 1% 4 times a day.
For all PSS patients whose intraocular pressure is higher than 30mmHg, also add brinzolamide
eye drops 3 times a day. Best corrected visual acuity, Goldmann intraocular pressure,
anterior section photographs, corneal endothelial cells，corneal confocal microscope,
Heidelberg retinal nerve analysis, Octopus visual field were examined on baseline and 1 week,
2 weeks, 3 weeks, 4 weeks after the treatment.